Approved For Marketing EXPANDED_ACCESS NCT03780140

Expanded Access to Cefiderocol for the Intravenous Treatment of Severe Gram Negative Bacterial Infections

Sponsor: Shionogi

Interventions Cefiderocol

Updated 6 times since 2019 Last updated: Feb 25, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03780140, this observational or N/A phase trial focuses on Bacterial Infections and remains ongoing. Sponsored by Shionogi, it has been updated 6 times since 2026, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Approved For Marketing
Jul 2024 — Sep 2024 [monthly]

Approved For Marketing
Jan 2021 — Jul 2024 [monthly]

Approved For Marketing
Mar 2020 — Jan 2021 [monthly]

Approved For Marketing

Status: Available → Approved For Marketing
Feb 2020 — Mar 2020 [monthly]

Available

▶ Show 1 earlier version

Jan 2019 — Feb 2020 [monthly]

Available

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shionogi

Data source: Shionogi Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.